IceCure gains on positive results from study in cancer patients

Icecure Medical

26/02/2024 13:28

** U.S.-listed shares of device maker IceCure Medical
 ICCM.O  rise 20.5% to $1.59 premarket
    ** Co says its ProSense System showed 100% tumor reduction
in patients with early-stage breast cancer in an independent
study 
    ** Says the study was performed on 39 women aged 60-92, who
had malignant lesions, and were deemed inoperable due to
advanced age and comorbidities, or who refused surgery
    ** ProSense is approved in Italy for numerous indications,
including breast cancer - ICCM
    ** Up to last close, stock was up 14.8% in the last 12
months

    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))